The FDA approved Foundayo (orforglipron), a new GLP-1 receptor agonist for chronic weight management, in a record-breaking 50 days. This marks the fastest approval for a new molecular entity since 2002. The drug is indicated for adults with obesity or overweight conditions alongside diet and exercise. Foundayo works by targeting GLP-1 receptors to control appetite and blood sugar levels, offering another option in the expanding weight loss medication landscape.
